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Achromobacter xylosoxidans is a non-glicose-fermenting environmental Gram-
negative rod with increasing recovering frequency from the respiratory tract of
Cystic Fibrosis (CF) patients. The pathogenic role of this microorganism is still
unclear including the knowledge of its virulence factors. We are searching for
potencial virulence factors in A. xylosoxidans strains isolated from CF pediatric
patients seen at the outpatient reference center at our State University Hospital. The
strains were identiﬁed by conventional tests, by automated Vitek II® and controlled
with LMG® reference strains and by PCR. The culture supernatants in BHI of 10
different clinical isolates of A. xylosoxidans and the LMG 1863 strain were assayed
for cytotoxic activity. Cytotoxic activity was observed only in H-460 (human lung
carcinoma), inducing blebbings and cellular death after 18 hours assays for all
strains. Microscopic analysis revealed rounding and membrane alterations followed
by detachment and cellular death. However no cytotoxic activity was veriﬁed on
HeLa (human cervix carcinoma), 3T3 (mouse ﬁbroblast) and Vero (green monkey
kidney) cells. These results suggest that the cytotoxic activity of A. xylosoxidans
to human lung cells (H-460) could be a potencial mechanism of pathogenicity that
may participate in the process of lung parenchyma destruction in cystic ﬁbrosis
patients and should be better investigated.
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We undertook a 4 year retrospective analysis of patients attending Papworth Hospital
Adult Cystic Fibrosis Unit from 2004−8.
Sputum surveillance for Non-Tuberculous Mycobacteria (NTM) was undertaken at
least annually and additionally when directed by abnormalities on CT scans or if
patients failed to respond to conventional antibiotics.
Between 2004−8 the annual incidence of new NTM positive sputum cultures
increased successively from 1.4% (3/217) in 2004−5, 2.3% (5/221) in 2005−6, 3.1%
(7/228) in 2006−7 and 4.3% (10/230) in 2007−8. Over this period, the most fre-
quently isolated species were M abscessus/chelonae (10/25), M avium/intracellulare
(5/25) and M kansasii (3/25). 10 patients during this period were diagnosed with
NTM disease of which 8 had M abscessus.
We have developed a treatment algorithm for M abscessus involving 2−3 weeks
induction therapy with 3/4 intravenous antibiotics followed by maintenance therapy
with 3/4 oral and 1/2 nebulised antibiotics with or without subcutaneous inter-
feron gamma. Exacerbations are treated with additional intravenous antibiotics for
2−3 weeks followed by augmentation of maintenance therapy.
A total of 12 patients have been treated for M abscessus/chelonae at our unit: 4
remain NTM free after >6 months of stopping treatment; 4 are on treatment and
have been culture negative for >6 months while 4 patients continue to culture M
abscessus despite maximum medical therapy.
We conclude that the incidence of NTM disease is increasing in adults with Cystic
Fibrosis, that M abscessus is the major pathgenen and that successful treatment is
possible in at least some patients.
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Bb is an aerobic gram(−) organism, causing highly transmissible acute respiratory
infections in mammals. Acute respiratory infections in humans – often immuno-
compromised – have been rarely reported. Nearly all had close contact with animals.
Cbi with Bb has been reported only once in CF
We have had 5 cases of cbi with Bb out of 170 CF patients (2.9%). Strains were
sent to a reference lab, which conﬁrmed the isolates, and studied them with pulsed
ﬁeld gel electrophoresis (PGFE). All were male aged 12−25 mean 15.5 years. None
was immunocompromised and only one had close contact with animals (dogs and
cats).PGFE showed that 4 (2 siblings) shared the same genetic pattern but except
in the two siblings, there was no contact among them. All had minimal or mild
pulmonary disease, and except the oldest one all had long cough-freee periods.
None had cbi with other organism. They all developed cbi with Bb only, except
the oldest one who also had intermitent S. aureus isolations. Three had no clinical
impairment, but both siblings developed daily cough shortly after colonization and
had a quick worsening in their clinical symptoms, chest X-ray, and pulmonary
function. FEV1 (% Pred)fell from 99% to 57% over 5 years in the older and from
100% to 78% over 2 years in the younger one.A poor correlation between antibiotic
sensitivity reports and clinical response was observed. Bb is an emerging organism
in CF which can cause cbi. It is potentially transmissible and may be asociated with
a steep clinical decline in some patients. We think that every patient in whom Bb
is grown should be isolated from other CF patients to prevent crossinfection.
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Inquilinus limosus (IL) is a recently described mucoid multiresistant Gram-negative
non fermenting species in the sputum of CF airways. Data were collected from all
French CF centres by the French Observatoire cepacia.
From 2002 to 2007, 15 colonizations were reported in 9 CF Centres. IL was
recovered from a Burkholderia cepacia selective medium and identiﬁed by means
of 16S rRNA analysis. The mean age at primocolonization was 11.6 (2−21). 7/15
colonizations were chronic, and the mean duration of the follow-up in these patients
was 3.8 (2−6) years. Of the 7 chronically colonized patients, 1 deceased 2 years
after the primocolonization and IL was strongly incriminated, 4 remain stable, and 2
deteriorated. Eradication of IL was unsuccessful despite several imipenem courses.
In conclusion, IL is increasingly recognized in CF, due to improved recovery and
identiﬁcation of this organism from the CF sputum. This study shows that it has to
be considered as having a potential clinical impact.
